We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Oral progestagens before menopause and breast cancer risk.
- Authors
Fabre, A.; Fournier, A.; Mesrine, S.; Desreux, J.; Gompel, A.; Boutron-Ruault, M.-C.; Clavel-Chapelon, F.
- Abstract
We examined the relationship between use of progestagen-only before menopause (except for mini-pills) after the age of 40 and invasive breast cancer risk in 73 664 women from the French E3N cohort study (mean age at start of follow-up, 51.8 years; mean duration of follow-up, 9.1 years). A total of 2390 cases of invasive breast cancer were diagnosed during follow-up. Risk estimates were calculated using the Cox proportional hazard model. Overall, ever use of progestagen before menopause was not significantly associated with risk (relative risk (RR): 1.01, 95% confidence interval: 0.93–1.11). However, we observed a significant increase in risk associated with the duration of use (P-value for trend: 0.012), current use of progestagens for longer than 4.5 years being significantly associated with risk (RR: 1.44, 95% confidence interval: 1.03–2.00). Prolonged use of progestagens after the age of 40 may be associated with an increased risk of breast cancer and the subject needs to be investigated further.British Journal of Cancer (2007) 96, 841–844. doi:10.1038/sj.bjc.6603618 www.bjcancer.com Published online 13 February 2007
- Subjects
DISEASE risk factors; CONTRACEPTIVE drugs; PROGESTATIONAL hormones; MENOPAUSE; BREAST cancer; DISEASES in women
- Publication
British Journal of Cancer, 2007, Vol 96, Issue 5, p841
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/sj.bjc.6603618